Search Results
Your search for L matches 3307 pages
Showing 2101 - 2150Consensus on Defining and Measuring Lymphedema Is Needed to Advance Efforts to Intervene Early and Prevent Progression
“Early intervention might prevent lymphedema progression,” Alphonse Taghian, MD, PhD, said at the 18th Annual Lynn Sage Breast Cancer Symposium in Chicago, but the lack of a universal definition of lymphedema and agreement on how to optimally measure it impedes phase III studies to test that...
Safety of Extreme Hypofractionation Reassuring in Intermediate-Risk Prostate Cancer
Giving patients larger fractions of radiation over shorter periods (ie, hypofractionation) is gaining ground in several types of cancers. This approach is attractive for patients’ convenience, shortening treatment and travel times, and also for resource utilization. Several studies have shown that ...
Study Finds PFS Benefit, but No Overall Survival Benefit, for Ipilimumab in Metastatic Castration-Resistant Prostate Cancer
Ipilimumab (Yervoy) was associated with prolonged progression-free survival—but not overall survival—compared with placebo in men with asymptomatic or minimally symptomatic chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases, according to a...
ESMO 2016: Antitumor Activity Demonstrated With Lurbinectedin in Patients With Metastatic Breast Cancer and BRCA Mutations
Lurbinectedin showed promising clinical benefit in pretreated patients with metastatic breast cancer and BRCA1 or BRCA2 mutations, including patients previously treated with platinum, according to phase II trial results presented by Balmaña et al at the 2016 European Society for Medical...
Benefits of Early Palliative Care Interventions Extend Beyond the Patient
A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...
Bridging the Gap in Oncology Care
The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...
Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
Risk of Metastasis With Active Monitoring in PSA-Detected Localized Prostate Cancer: The ProtectT Trial
The ProtecT study findings1 are provocative. Despite having a control arm of active monitoring with serial prostate-specific antigen (PSA) testing, as compared with watchful waiting in the prior randomized trials (ie, SPCG-42 and PIVOT3), and also enrolling men with more favorable-risk disease...
Similar 10-Year Survival With Active Monitoring, Surgery, or Radiotherapy for PSA-Detected Clinically Localized Prostate Cancer
In the UK ProtecT trial reported in The New England Journal of Medicine, Freddie C. Hamdy, FRCS, FMedSci, of the University of Oxford, and colleagues found no significant differences in prostate cancer–specific or overall mortality among men with clinically localized prostate cancer detected by...
Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
Emily L. Sedgwick, MD, Receives Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism
Emily L. Sedgwick, MD, Associate Professor of Breast Imaging in the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center, has been named the 2016 recipient of the Ben and Margaret Love Foundation Bobby Alford Award for...
Michael Maitland, MD, PhD, Named Director of Therapeutics for the Inova Center for Personalized Health
Inova Health System is pleased to welcome Michael Maitland, MD, PhD, where he will serve as the new Director of Therapeutics for the Inova Center for Personalized Health and as Associate Director of Cancer Therapeutics for the Inova Schar Cancer Institute. Dr. Maitland comes to Inova from the...
2016 Lasker Awards Honor Scientists for Basic and Clinical Medical Research, Special Achievement
The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. Kaelin, MD; Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS; and Gregg L. Semenza, MD, PhD for basic medical research; Ralf F.W. Bartenschlager, PhD; Charles M. Rice, PhD;...
The Halifax Project: A New Approach to Combination Therapy
On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...
Recognizing the Unique Experiences of Cancer Among Adolescent and Young Adult Survivors
Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...
Cancer Survivorship Symposium Brings Together Oncologists and Primary Care Providers to Improve Patient Care
Significant advances in cancer care and treatment have led to a steady increase in survivorship—currently, more than 15.5 million cancer survivors are living in the United States. This number is only expected to grow, with an estimate of more than 20 million American cancer survivors in 2026.1 A...
Stacey Ann Carter, MD, Joins Lester and Sue Smith Breast Center, Department of Surgery at Baylor
Stacey Ann Carter, MD, has joined the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine and the Department of Surgery as Assistant Professor. Dr. Carter joins the Breast Center team as a...
Improving Management of Sexual Problems for Cancer Survivors
What do up to 60% of cancer survivors have in common? Answer: some type of long-term sexual dysfunction. How many cancer survivors seek professional help for sexual problems? Answer: less than 20%. Even when they do seek help, they may not be successful in finding professionals with expertise in...
Expert Point of View: Benjamin L. Judson, MD
“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real problem,” commented session...
Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Palliative Care 2016: Rehospitalization of Patients With Advanced Cancer in the Year After Diagnosis
Among individuals with advanced cancer, frequent hospitalization is often at odds with patient preference and is increasingly viewed as a hallmark of poor quality care. Hospitalization contributes substantially to costs and regional spending variation in this population, but patterns and reasons...
Durable Responses Reported With Avelumab in Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma
In a phase II trial reported in The Lancet Oncology, Kaufman et al found that the anti–PD-L1 (programmed cell death ligand 1) monoclonal antibody avelumab produced durable responses in patients with stage IV Merkel cell carcinoma progressing after cytotoxic chemotherapy. Study Details In...
Study Finds HIV Infection Linked to Reduced Survival Among Women With Cervical Cancer in Botswana
Despite access to and use of antiretroviral therapy, HIV (human immunodeficiency virus) infection was associated with reduced survival in women with cervical cancer in Botswana, according to a study reported by Dryden-Peterson et al in the Journal of Clinical Oncology. Study Details The study...
Randy L. Wei, MD, PhD, on Radiation Oncologists and Palliative Care
Randy L. Wei, MD, PhD, of the University of California, Irvine, discusses findings from a survey that focused on ASTRO members who assessed their ability to deliver palliative and supportive care, and their access to continuing medical education on the topic (Abstract 105).
ECOG-ACRIN Group Co-Chair Robert L. Comis, MD, to Step Down in 2019
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced that Robert L. Comis, MD, Professor of Medicine at Drexel University, is stepping down from his position as Group Co-Chair of the organization. His departure, effective February 28, 2019, will coincide with the end of ECOG-ACRIN’s current ...
Duncan Comprehensive Cancer Center at Baylor Launches Specialty Team for Comprehensive Esophageal Cancer Care
The National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine has formed a new multispecialty group to provide expert, state-of-the-art esophageal cancer care, from assessing risk, screening, and prevention to diagnosis, treatment, and...
New ASCO-SITC Symposium Dives Into Immuno-Oncology Research and Clinical Care
Advances in the field of immuno-oncology are revolutionizing cancer care. Ongoing progress with immune checkpoint agents, immune system boosts, cancer vaccines, and monoclonal antibodies continues to yield new and exciting results. However, with the benefits of rapid expansion comes the challenge...
Addressing the Significant Disparities and Barriers to Health Care Experienced by LGBT Cancer Survivors
In 2011, the Institute of Medicine (IOM) published its landmark report “The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding,” which recognized the scarcity of research in lesbian, gay, bisexual, and transgender (LGBT) individuals and the...
Venetoclax Produces High Response Rate in Relapsed or Refractory CLL With 17p Deletion
In a pivotal phase II study reported in The Lancet Oncology, Stephan Stilgenbauer, MD, of Ulm University, Germany, and colleagues found that the BCL2 inhibitor venetoclax (ABT-199) produced a high response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p ...
Effect of Radiosurgery Alone vs With Whole-Brain Radiotherapy on Cognitive Function in Patients With Brain Metastases
Physicians from Carolinas HealthCare System’s Neurosciences Institute and Levine Cancer Institute are among the authors of a recent study published by Brown et al in JAMA.1 The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery alone, compared...
Global Curriculum in Surgical Oncology Outlined by Society of Surgical Oncology and European Society of Surgical Oncology
As reported by Chandrakanth Are, MBBS, MBA, FRCS, FACS, of the University of Nebraska Medical Center, Omaha, and colleagues at the Society of Surgical Oncology (SSO) and European Society of Surgical Oncology (ESSO), the rising global burden of cancer and inequalities in surgical oncology education ...
President Obama Names Margaret Spitz, MPH, to National Cancer Advisory Board
Margaret Spitz, MPH, Professor in the National Cancer Institute (NCI)-designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, has been appointed by President Barack Obama as a member of the National Cancer Advisory Board (NCAB). A renowned expert in molecular...
Interim PET-Adapted Treatment in Advanced Hodgkin Lymphoma
The ability to cure a majority of patients with advanced Hodgkin lymphoma is one of the major milestones of success in the combination chemotherapy era. It has been over 40 years since Bonadonna and colleagues in Milan developed the ABVD regimen (doxorubicin, bleomycin, vinblastine, and...
Hypofractionated Radiotherapy for Localized Prostate Cancer: A New Standard of Care?
For at least the past quarter of a century, radiobiologists and radiation oncologists have debated the role of hypofractionation (fewer total fractions with a higher dose per fraction) for prostate cancer. The debate stems from the unique radiobiology of prostate cancer and the best means to...
Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma
In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...
For High-Grade and Aggressive Non-Hodgkin Lymphomas, Treat Adults Like Children
Outcomes for adults with high-grade and aggressive non-Hodgkin lymphomas (NHLs) appear to be better when these patients are treated with pediatric-inspired protocols, according to Mitchell S. Cairo, MD, Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria...
Expert Point of View: Michael L. Hinni, MD
“Endoscopic transoral surgeons have used corticosteroids for years before, during, and after transoral operations to prevent presumptive airway edema and to reduce the risks of tracheostomy,” commented one of the session co-moderators, Michael L. Hinni, MD, Chair of the Department of...
Early Relapse in Follicular Lymphoma: Clinical Trial Data May Guide Management Decisions
Approximately 20% of patients with follicular lymphoma will relapse within 2 years of diagnosis. Although the optimal management of these patients has not been established, clinicians may be guided by data from recent clinical trials, according to Nathan H. Fowler, MD, Associate Professor and...
European Studies Compare Conventional vs Hypofractionated Radiotherapy for Localized Prostate Cancer
Two recent European phase III trials with different study designs focused on hypofractionated vs conventional radiotherapy in localized prostate cancer. Investigators in the CHHiP trial1 showed that the hypofractionated approach is noninferior to standard fractionation, with no increase in side...
FDA Accepts New Drug Application, Grants Priority Review of Rucaparib for the Treatment of Advanced BRCA-Mutant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has accepted Clovis Oncology’s New Drug Application (NDA) for accelerated approval of rucaparib and granted Priority Review status to the application with a Prescription Drug User Fee Act date of February 23, 2017. Rucaparib is an...
Cancer Research Institute to Honor Three Scientists for Outstanding Contributions to Cancer Immunotherapy Research
The Cancer Research Institute (CRI), a nonprofit organization established in 1953 to advance biomedical research with the goal of developing lifesaving immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields...
Hypofractionated Radiotherapy: Balancing Benefits vs Risks in Men With Localized Prostate Cancer
Radiation for prostate cancer typically requires 40 to 45 daily treatments, given over 8 to 9 weeks. Long fractionation schemes are chosen for most cancers, because they allow for tumor killing while reducing the potential for injury to normal tissue. However, the radiobiology of prostate cancer...
Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy
Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib...
Four Young Scientists Receive Damon Runyon–Sohn Pediatric Cancer Research Fellowship Awards
The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon–Sohn Pediatric Cancer Research Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research. The...
Chamomile
Scientific Name: Matricaria recutita, Chamomilla recutita, Matricaria chamomilla Common Names: Hungarian chamomile, wild chamomile Overview An aromatic annual herb prevalent in Europe, North Africa, and Northwest Asia, chamomile has been used as a medicinal plant for several centuries. It has been ...
Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years
The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...
Late Cardiac Effects of Cancer Treatment
The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...
AACR, Pancreatic Cancer Action Network Awards Research Grants to Early-Career Investigators
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network awarded nine grants to outstanding scientists who will undertake novel research in the field of pancreatic cancer. “By recruiting the brightest scientists with the most novel ideas, we continue to build a ...
Outcomes With Rituximab in DLBCL: Does Gender Matter?
For diffuse large B-cell lymphoma, does the dose of rituximab (Rituxan) matter? Are there patient characteristics that determine outcomes as well as the optimal dose? These questions were explored at the 2016 Pan Pacific Lymphoma Conference by Matthew A. Lunning, DO, Assistant Professor of...
Combination Obinutuzumab Regimen Active in Aggressive Diffuse Large B-Cell Lymphoma
In a small phase Ib/II study, 100% of patients with newly diagnosed diffuse large B-cell lymphoma evaluated thus far responded to treatment with obinutuzumab (Gazyva), lenalidomide (Revlimid), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), investigators from the University of...
